StockOptionsChannel.com

Stock Options Channel is a stock options research website, aimed at financial advisors and retail investors trying to maximize the opportunities in stock options and using puts and calls to gain yield on their investments. The site includes a number of ground-breaking features that allow investors to dig deeper into interesting stock options opportunities, including the site's proprietary YieldBoost ranking system. Each week we put out a free newsletter sharing the results of our YieldBoost rankings, and throughout each day we share even more detailed reports to subscribers to our premium service. On the CALLS side of the options chain, the YieldBoost formula looks for the highest premiums a call seller can receive (expressed in terms of the extra yield against the current share price - the boost - delivered by the option premium), with strikes that are out-of-the-money with low odds of the stock being called away. On the PUTS side of the options chain, the YieldBoost formula considers that the option seller makes a commitment to put up a certain amount of cash to buy the stock at a given strike, and looks for the highest premiums a put seller can receive (expressed in terms of the extra yield against the cash commitment - the boost - delivered by the option premium), with strikes that are out-of-the-money with low odds of the stock being put to the option seller.

Recent Articles By The Author

YieldBoost RRD From 5% To 13.6% Using Options

YieldBoost RRD From 5% To 13.6% Using Options

Shareholders of Donnelley & Sons Company looking to boost their income beyond the stock's 5% annualized dividend yield can sell the September covered call at the $13 strike and collect the premium based on the 45 cents bid, which annualizes to an additional 8.6% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost), for a total of 13.6% annualized rate in the scenario where the stock is not called away. Any upside above $13 would be lost if the stock rises there and is called away, but RRD shares would have to climb 16.9% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 21% return from this trading level, in addition to any dividends collected before the stock was called.

Commit To Buy TG Therapeutics At $10, Earn 29.1% Annualized Using Options

Commit To Buy TG Therapeutics At $10, Earn 29.1% Annualized Using Options

Investors eyeing a purchase of TG Therapeutics Inc shares, but cautious about paying the going market price of $11.43/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $10 strike, which has a bid at the time of this writing of $1.15.

Commit To Purchase Sangamo Therapeutics At $3, Earn 20.4% Annualized Using Options

Commit To Purchase Sangamo Therapeutics At $3, Earn 20.4% Annualized Using Options

Investors eyeing a purchase of Sangamo Therapeutics Inc stock, but tentative about paying the going market price of $4.18/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 50 cents.

Commit To Buy PTC Therapeutics At $8, Earn 26% Annualized Using Options

Commit To Buy PTC Therapeutics At $8, Earn 26% Annualized Using Options

Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $8.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.70.

Commit To Purchase Seres Therapeutics At $7.50, Earn 10.5% Annualized Using Options

Commit To Purchase Seres Therapeutics At $7.50, Earn 10.5% Annualized Using Options

Investors considering a purchase of Seres Therapeutics Inc stock, but cautious about paying the going market price of $11.14/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $7.50 strike, which has a bid at the time of this writing of 25 cents.